Can binimetinib, encorafenib and masitinib be more efficacious than currently available mutation-based targeted therapies for melanoma treatment?

Megan C. Turner, Kara Rossfeld, April K.S. Salama, Douglas Tyler, Georgia Beasley

Research output: Contribution to journalReview article

4 Scopus citations

Abstract

Introduction: Historically, there were few effective and durable treatments for metastatic melanoma. Recently, mutation based targeted therapies have revolutionized treatment and outcomes for patients with metastatic melanoma. Specifically, inhibitors aimed at BRAF, NRAS, and C-KIT mutations are now commonly used in treatment for patients harboring the specific mutations. Areas covered: A brief review of current BRAF, NRAS, and C-KIT inhibitors provides background for a thorough review of newly developed agents namely binimetinib, a MEK inhibitor, encorafenib a BRAF inhibitor, and masitinib which inhibits C-KIT. Expert opinion: While the 3 novel agents reviewed here have potential for use in melanoma, optimal utilization will occur once a more personalized approach incorporating genomic, proteomic, and immunologic data guides therapeutic decisions.

Original languageEnglish (US)
Pages (from-to)487-495
Number of pages9
JournalExpert Opinion on Pharmacotherapy
Volume18
Issue number5
DOIs
StatePublished - Mar 24 2017

Keywords

  • BRAF
  • c-kit
  • MEK
  • Melanoma
  • targeted therapy

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Can binimetinib, encorafenib and masitinib be more efficacious than currently available mutation-based targeted therapies for melanoma treatment?'. Together they form a unique fingerprint.

  • Cite this